User menu

A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.

Bibliographic reference Andreu, Franc ; Colom, Helena ; Elens, Laure ; van Gelder, Teun ; van Schaik, Ronald H N ; et. al. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.. In: Clinical Pharmacokinetics, Vol. 56, p. 963-975 (2017)
Permanent URL http://hdl.handle.net/2078.1/191541
  1. Matas A. J., Smith J. M., Skeans M. A., Lamb K. E., Gustafson S. K., Samana C. J., Stewart D. E., Snyder J. J., Israni A. K., Kasiske B. L., OPTN/SRTR 2011 Annual Data Report: Kidney, 10.1111/ajt.12019
  2. Venkataramanan Raman, Swaminathan Arun, Prasad Tata, Jain Ashok, Zuckerman Sheila, Warty Vijay, McMichael John, Lever Jacqueline, Burckart Gilbert, Starzl Thomas, Clinical Pharmacokinetics of Tacrolimus : , 10.2165/00003088-199529060-00003
  3. Wallemacq Pierre, Armstrong Victor W, Brunet Merce, Haufroid Vincent, Holt David W, Johnston Atholl, Kuypers Dirk, Meur Yannick Le, Marquet Pierre, Oellerich Michael, Thervet Eric, Toenshoff Burkhand, Undre Nas, Weber Lutz T, Westley Ian S, Mourad Michel, Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference : , 10.1097/ftd.0b013e318198d092
  4. FDA. Draft guidance on tacrolimus 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM181006.pdf . Accessed 07 Sept 2016.
  5. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation : , 10.2165/00003088-200443100-00001
  6. Astellas Pharma US. Prograf: highlights of prescribing information. https://www.us.astellas.com/docs/prograf.pdf . Accessed 07 Sept 2016.
  7. Wallemacq P. E., Furlan V., Möller A., Schäfer A., Stadler P., Firdaous I., Taburet A -M., Reding R., De Clety S. Clement, De Ville De Goyet J., Sokal E., Lykavieris L., Van Leeuw V., Bernard O., Otte J. B., Undre N. A., Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients, 10.1007/bf03192295
  8. Provenzani Alessio, Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients, 10.3748/wjg.v19.i48.9156
  9. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients : , 10.2165/00003088-200746010-00002
  10. Zahir H., McCaughan G., Gleeson M., Nand R. A., McLachlan A. J., Factors affecting variability in distribution of tacrolimus in liver transplant recipients : Factors affecting distribution of tacrolimus, 10.1046/j.1365-2125.2003.02008.x
  11. van Maarseveen Erik M., Rogers Christin C., Trofe-Clark Jennifer, van Zuilen Arjan D., Mudrikova Tania, Drug–Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review, 10.1089/apc.2012.0169
  12. Mancinelli L, The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups, 10.1067/mcp.2001.113183
  13. Bekersky Ihor, Dressler Dawna, Mekki Qais A., Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects, 10.1177/00912700122009999
  14. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990;22:57–9.
  15. Thervet Eric, Anglicheau Dany, King Barry, Schlageter Marie-H??l??ne, Cassinat Bruno, Beaune Philippe, Legendre Christophe, Daly Ann K., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 : , 10.1097/01.tp.0000090753.99170.89
  16. Elens Laure, Capron Arnaud, Kerckhove Valérie Van, Lerut Jan, Mourad Michel, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation : , 10.1097/fpc.0b013e3282e9a533
  17. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I, CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients, 10.1038/sj.clpt.6100039
  18. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/01.tp.0000151766.73249.12
  19. Zhang Xin, Liu Zhi-hong, Zheng Jing-min, Chen Zhao-hong, Tang Zheng, Chen Jin-song, Li Lei-shi, Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation, 10.1111/j.1399-0012.2005.00370.x
  20. Hesselink Dennis A., Bouamar Rachida, Elens Laure, van Schaik Ron H. N., van Gelder Teun, The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation, 10.1007/s40262-013-0120-3
  21. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721–6.
  22. Åsberg Anders, Midtvedt Karsten, van Guilder Mike, Størset Elisabet, Bremer Sara, Bergan Stein, Jelliffe Roger, Hartmann Anders, Neely Michael N., Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation, 10.1111/tri.12194
  23. Lloberas N, Andreu F, van Gelder T, et al. Impact of CYP3A4*22, CYP3A5*1 and POR*28 polymorphisms on tacrolimus dose optimization and the outcome of kidney transplantation [abstract no. 307]. In: 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology; 11–15 Oct 2015; Rotterdam. http://iatdmct2015.org/abstracts/307-2/ . Accessed 27 Sept 2016.
  24. Størset Elisabet, Holford Nick, Midtvedt Karsten, Bremer Sara, Bergan Stein, Åsberg Anders, Importance of hematocrit for a tacrolimus target concentration strategy, 10.1007/s00228-013-1584-7
  25. Jacobo-Cabral Carlos Orlando, García-Roca Pilar, Romero-Tejeda Elba Margarita, Reyes Herlinda, Medeiros Mara, Castañeda-Hernández Gilberto, Trocóniz Iñaki F., Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation : Role of CYP3A5 genotype and formulation type on tacrolimus PK, 10.1111/bcp.12649
  26. Musuamba Flora Tshinanu, Fazio Vincent Di, Vanbinst Roger, Wallemacq Pierre, A Fast Ultra-Performance Liquid Chromatography Method for Simultaneous Quantification of Mycophenolic Acid and Its Phenol- and Acyl-Glucuronides in Human Plasma : , 10.1097/ftd.0b013e318191897d
  27. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  28. Zuo Xiao-cong, Ng Chee M., Barrett Jeffrey S., Luo Ai-jing, Zhang Bi-kui, Deng Chen-hui, Xi Lan-yan, Cheng Ke, Ming Ying-zi, Yang Guo-ping, Pei Qi, Zhu Li-jun, Yuan Hong, Liao Hai-qiang, Ding Jun-jie, Wu Di, Zhou Ya-nan, Jing Ning-ning, Huang Zhi-jun, Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients : a population pharmacokinetic analysis, 10.1097/fpc.0b013e32835fcbb6
  29. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  30. Elens L, Capron A, van Schaik RHN, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35:608–16.
  31. Elens Laure, Bouamar Rachida, Shuker Nauras, Hesselink Dennis A., van Gelder Teun, van Schaik Ron H. N., Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks : Pharmacogenetics of calcineurin inhibitors in kidney transplantation, 10.1111/bcp.12253
  32. Andreu Franc, Colom Helena, Grinyó Josep M., Torras Joan, Cruzado Josep M., Lloberas Nuria, Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients : , 10.1097/ftd.0000000000000134
  33. Grinyó Josep M., Ekberg Henrik, Mamelok Richard D., Oppenheimer Federico, Sánchez-Plumed Jaime, Gentil Miguel Angel, Hernandez Domingo, Kuypers Dirk R., Brunet Mercé, The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy, 10.1093/ndt/gfp162
  34. Capron Arnaud, Mourad Michel, De Meyer Martine, De Pauw Luc, Eddour Djamila Chaib, Latinne Dominique, Elens Laure, Haufroid Vincent, Wallemacq Pierre, CYP3A5andABCB1polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, 10.2217/pgs.10.43
  35. Lindbom Lars, Pihlgren Pontus, Jonsson Niclas, PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM, 10.1016/j.cmpb.2005.04.005
  36. Savic Radojka M., Jonker Daniël M., Kerbusch Thomas, Karlsson Mats O., Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies, 10.1007/s10928-007-9066-0
  37. Karlsson M. O., Sheiner L. B., The importance of modeling interoccasion variability in population pharmacokinetic analyses, 10.1007/bf01113502
  38. Yamaoka Kiyoshi, Nakagawa Terumichi, Uno Toyozo, Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations, 10.1007/bf01117450
  39. Savic Radojka M., Karlsson Mats O., Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, 10.1208/s12248-009-9133-0
  40. Jonsson E. Niclas, Karlsson Mats O., 10.1023/a:1011970125687
  41. Sheiner Lewis B., Beal Stuart L., Some suggestions for measuring predictive performance, 10.1007/bf01060893
  42. Bergstrand Martin, Hooker Andrew C., Wallin Johan E., Karlsson Mats O., Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models, 10.1208/s12248-011-9255-z
  43. Yano Yoshitaka, Beal Stuart L., Sheiner Lewis B., 10.1023/a:1011555016423
  44. Elens Laure, van Gelder Teun, Hesselink Dennis A, Haufroid Vincent, van Schaik Ron HN, CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy, 10.2217/pgs.12.187
  45. Staatz C, Population pharmacokinetics of tacrolimus in adult kidney transplant recipients, 10.1067/mcp.2002.129304
  46. Benkali Khaled, Prémaud Aurelie, Picard Nicolas, Rérolle Jean-Philippe, Toupance Olivier, Hoizey Guillaume, Turcant Alain, Villemain Florence, Le Meur Yannick, Marquet Pierre, Rousseau Annick, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients : , 10.2165/11318080-000000000-00000
  47. Woillard Jean-Baptiste, de Winter Brenda C. M., Kamar Nassim, Marquet Pierre, Rostaing Lionel, Rousseau Annick, Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf® and once daily Advagraf® : Bayesian estimator for both Prograf® and Advagraf®, 10.1111/j.1365-2125.2010.03837.x
  48. Moes D J A R, Swen J J, den Hartigh J, van der Straaten T, van der Heide J J Homan, Sanders J S, Bemelman F J, de Fijter J W, Guchelaar H J, Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation, 10.1038/psp.2013.78
  49. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  50. Jacobson P. A., Schladt D., Oetting W. S., Leduc R., Guan W., Matas A. J., Israni A., Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs : Calcineurin Inhibitors in the Elderly, 10.1111/j.1600-6143.2012.04232.x
  51. Kuypers Dirk R.J., de Loor Henriette, Naesens Maarten, Coopmans Tamara, de Jonge Hylke, Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients : , 10.1097/fpc.0000000000000095
  52. Størset Elisabet, Åsberg Anders, Skauby Morten, Neely Michael, Bergan Stein, Bremer Sara, Midtvedt Karsten, Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study : , 10.1097/tp.0000000000000708
  53. Andrews Louise M, Riva Natalia, de Winter Brenda C, Hesselink Dennis A, de Wildt Saskia N, Cransberg Karlien, van Gelder Teun, Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients, 10.1517/17425255.2015.1033397
  54. Shuker Nauras, Shuker Lamis, van Rosmalen Joost, Roodnat Joke I., Borra Lennaert C. P., Weimar Willem, Hesselink Dennis A., van Gelder Teun, A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation, 10.1111/tri.12798
  55. Whalen Henry R., Glen Julie A., Harkins Victoria, Stevens Katherine K., Jardine Alan G., Geddes Colin C., Clancy Marc J., High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime : , 10.1097/tp.0000000000001129
  56. Vanhove T, Annaert P, Lambrechts D, Kuypers D R J, Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype, 10.1038/tpj.2016.49